• Gökhan Çiçek, Harun Kundi, Mehmet Bozbay, Cagrı Yayla, and Hüseyin Uyarel.
• aDepartment of Cardiology, Ankara Numune Education and Research Hospital bDepartment of Cardiology, Ankara Yuksek Ihtisas Hospital, Ankara cDepartment of Cardiology, Siyami Ersek Center for Cardiovascular Surgery dDepartment of Cardiology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey.
• Coron. Artery Dis. 2016 May 1; 27 (3): 176-84.

BackgroundMonocyte to HDL-C ratio (MHR) represents a simple assessment method for inflammatory status. The aim of the present study was to investigate whether MHR may be of short-term and long-term prognostic value in ST-elevation myocardial infarction (STEMI) patients who have undergone a primary percutaneous coronary intervention (PCI).Materials And MethodsA total of 682 consecutive STEMI patients who underwent successful primary PCI between March 2013 and September 2015 were included in this study. Patients were divided into groups according to their admission MHR values. Clinical follow-up data of participating patients were obtained through an outpatient examination 30 months after PCI.ResultsThe study population included 172 patients with an MHR less than 1.16 (Q1), 169 patients with an MHR 1.16-1.59 (Q2), 161 patients with an MHR 1.60-2.21 (Q3), and 180 patients with an MHR greater than 2.21 (Q4). Rates of in-hospital mortality, major adverse cardiovascular events, cardiopulmonary resuscitation, dialysis, use of inotropic agents, shock, late mortality, target vessel revascularization, stroke, and reinfarct were higher in the Q4 group compared with the other MHR quartile groups.ConclusionThe results of this study have indicated that admission MHR is associated independently and significantly with short-term and long-term mortality in STEMI patients who undergo successful primary PCI.

50 keywords...

hide…